Spruce Biosciences (SPRB) Projected to Post Quarterly Earnings on Thursday

Key Points

• Spruce Biosciences will report its Q4 2025 results before the market opens on Thursday, March 12, with analysts forecasting a loss of about ($9.1575) per share; a conference call is scheduled for Friday, March 13 at 9:30 AM ET.
• The stock is highly volatile—it opened at $57.54, has a 52‑week range of $4.28 to $240.00, a beta of 3.62 and a market cap of roughly $61.6 million—reflecting large price swings despite a small market value.
• Analyst coverage is mixed: the consensus rating is "Hold" with an average price target of $187.90, based on four Buys, three Holds and one Sell.

Spruce Biosciences (NASDAQ:SPRB - Get Free Report) is expected to be releasing its Q4 2025 results before the market opens on Thursday, March 12th. Analysts expect Spruce Biosciences to post earnings of ($9.1575) per share for the quarter. Individuals can find conference call details on the company's upcoming Q4 2025 earning report page for the latest details on the call scheduled for Friday, March 13, 2026 at 9:30 AM ET.

Spruce Biosciences Stock Performance

Shares of SPRB stock opened at $57.54 on Thursday. The firm's 50-day moving average is $73.76 and its 200-day moving average is $74.07. The stock has a market cap of $61.57 million, a price-to-earnings ratio of -0.68 and a beta of 3.62. Spruce Biosciences has a 52-week low of $4.28 and a 52-week high of $240.00.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on SPRB shares. Oppenheimer started coverage on Spruce Biosciences in a research report on Tuesday, December 23rd. They set an "outperform" rating and a $283.00 price target on the stock. HC Wainwright reiterated a "buy" rating and set a $200.00 target price (down from $220.00) on shares of Spruce Biosciences in a research note on Thursday, February 19th. Citigroup restated a "market perform" rating on shares of Spruce Biosciences in a research note on Tuesday, November 11th. Citizens Jmp set a $259.00 price target on Spruce Biosciences in a report on Tuesday, November 11th. Finally, Wall Street Zen downgraded shares of Spruce Biosciences from a "hold" rating to a "sell" rating in a report on Saturday, December 27th. Four equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Hold" and an average price target of $187.90.

Institutional Investors Weigh In On Spruce Biosciences

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Cable Car Capital LP bought a new position in Spruce Biosciences during the third quarter worth about $239,000. SkyView Investment Advisors LLC bought a new stake in Spruce Biosciences in the 4th quarter valued at about $261,000. State Street Corp acquired a new position in shares of Spruce Biosciences during the 4th quarter worth approximately $558,000. Superstring Capital Management LP bought a new position in shares of Spruce Biosciences during the fourth quarter worth approximately $1,057,000. Finally, Geode Capital Management LLC acquired a new stake in shares of Spruce Biosciences in the fourth quarter valued at approximately $1,109,000. Institutional investors and hedge funds own 91.71% of the company's stock.

Spruce Biosciences Company Profile

Spruce Biosciences, Inc is a clinical-stage biopharmaceutical company dedicated to developing therapies for rare endocrine and dermatological disorders. Headquartered in San Diego, California, Spruce focuses on conditions with significant unmet medical needs, employing a precision medicine approach to identify and advance treatment candidates through late-stage clinical trials.

The company's lead asset, tildacerfont, is an oral corticotropin-releasing factor type 1 (CRF1) receptor antagonist being evaluated for the treatment of congenital adrenal hyperplasia (CAH), a genetic disorder characterized by insufficient cortisol production and excess androgen levels.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.